CR20140251A - Inhibidores de pak para el tratamiento del síndrome del x frágil - Google Patents

Inhibidores de pak para el tratamiento del síndrome del x frágil

Info

Publication number
CR20140251A
CR20140251A CR20140251A CR20140251A CR20140251A CR 20140251 A CR20140251 A CR 20140251A CR 20140251 A CR20140251 A CR 20140251A CR 20140251 A CR20140251 A CR 20140251A CR 20140251 A CR20140251 A CR 20140251A
Authority
CR
Costa Rica
Prior art keywords
fragile
syndrome
treatment
pak inhibitors
pak
Prior art date
Application number
CR20140251A
Other languages
English (en)
Inventor
John C Mckew
Wenwei Huang
David Campbell
Sergio G Duron
Mark Behnke
Min Shen
Original Assignee
Afraxis Holdings Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afraxis Holdings Inc, Us Health filed Critical Afraxis Holdings Inc
Publication of CR20140251A publication Critical patent/CR20140251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20140251A 2011-11-04 2014-05-26 Inhibidores de pak para el tratamiento del síndrome del x frágil CR20140251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161555902P 2011-11-04 2011-11-04

Publications (1)

Publication Number Publication Date
CR20140251A true CR20140251A (es) 2014-08-20

Family

ID=48192852

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20140251A CR20140251A (es) 2011-11-04 2014-05-26 Inhibidores de pak para el tratamiento del síndrome del x frágil
CR20140250A CR20140250A (es) 2011-11-04 2014-05-26 Inhibidores de pak para el tratamiento de los transtornos de proliferación celular

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140250A CR20140250A (es) 2011-11-04 2014-05-26 Inhibidores de pak para el tratamiento de los transtornos de proliferación celular

Country Status (20)

Country Link
US (2) US20130116263A1 (es)
EP (2) EP2773643A4 (es)
JP (2) JP2015501786A (es)
KR (2) KR20140096098A (es)
CN (2) CN104093717A (es)
AR (1) AR089175A1 (es)
AU (2) AU2012327183A1 (es)
BR (2) BR112014010631A2 (es)
CA (2) CA2854471A1 (es)
CL (2) CL2014001131A1 (es)
CO (1) CO7030960A2 (es)
CR (2) CR20140251A (es)
EA (2) EA201490927A1 (es)
IL (2) IL232154A0 (es)
MA (2) MA35660B1 (es)
MX (2) MX2014005296A (es)
PH (2) PH12014500956A1 (es)
SG (2) SG11201401996TA (es)
TW (1) TW201326169A (es)
WO (2) WO2013067434A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580216A4 (en) * 2010-06-10 2014-07-23 Afraxis Holdings Inc 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
MX343893B (es) 2011-11-04 2016-11-28 Hoffmann La Roche Nuevos derivados de aril-quinolina.
WO2014144737A1 (en) 2013-03-15 2014-09-18 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
TW201516045A (zh) * 2013-07-26 2015-05-01 Hoffmann La Roche 絲胺酸／蘇胺酸激酶抑制劑
RU2721723C2 (ru) * 2014-02-07 2020-05-21 Принсипиа Биофарма, Инк. Производные хинолона как ингибиторы рецептора фактора роста фибробластов
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA3013959C (en) * 2016-02-17 2024-05-28 Nuralogix Corporation System and method for detecting physiological state
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109415366B (zh) * 2016-06-23 2022-02-22 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2018013466A2 (en) * 2016-07-15 2018-01-18 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of endocrine resistance in breast cancer
CN106818805A (zh) * 2016-12-27 2017-06-13 东莞市联洲知识产权运营管理有限公司 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用
CN107083428B (zh) * 2017-04-10 2020-09-25 徐州医科大学 Pak5在癌症诊断预后治疗及药物筛选中的应用
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
WO2020142612A1 (en) * 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
CN112213400B (zh) * 2019-07-09 2022-06-07 四川弘合生物科技有限公司 一种β-榄香烯及其有关物质的检测方法
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CN117858879A (zh) * 2021-01-15 2024-04-09 南京再明医药有限公司 Cdk2/4/6抑制剂及其制备方法和应用
CN113046323A (zh) * 2021-04-02 2021-06-29 四川农业大学 一种基于miR-532-5p及其靶基因调控卵巢颗粒细胞的方法
JP2024544632A (ja) 2021-12-03 2024-12-03 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物
WO2025257301A1 (en) * 2024-06-13 2025-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of neurofibromatosis type 2 by inhibitors of g6pd, acsl3 and/or oxsm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
EP2112150B1 (en) * 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010071846A2 (en) * 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
PH12012500692A1 (en) * 2009-10-09 2012-11-12 Afraxis Inc 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US8912203B2 (en) * 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2580216A4 (en) * 2010-06-10 2014-07-23 Afraxis Holdings Inc 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Also Published As

Publication number Publication date
PH12014500956A1 (en) 2014-06-30
BR112014010420A2 (pt) 2017-04-25
AU2012327183A1 (en) 2013-05-30
EP2773643A1 (en) 2014-09-10
MX2014005292A (es) 2014-09-11
CL2014001132A1 (es) 2014-08-22
CA2854471A1 (en) 2013-05-10
MX2014005296A (es) 2014-08-27
US20130116263A1 (en) 2013-05-09
CR20140250A (es) 2014-08-20
AR089175A1 (es) 2014-08-06
KR20140096098A (ko) 2014-08-04
CA2854462A1 (en) 2013-05-10
SG11201401914WA (en) 2014-05-29
MA35660B1 (fr) 2014-11-01
MA35661B1 (fr) 2014-11-01
JP2015501786A (ja) 2015-01-19
SG11201401996TA (en) 2014-05-29
CN104039786A (zh) 2014-09-10
EA201490927A1 (ru) 2014-10-30
IL232154A0 (en) 2014-05-28
CL2014001131A1 (es) 2014-08-22
EA201490925A1 (ru) 2014-09-30
CN104093717A (zh) 2014-10-08
AU2012327187A1 (en) 2013-05-23
EP2773642A1 (en) 2014-09-10
WO2013067423A1 (en) 2013-05-10
US20150031693A1 (en) 2015-01-29
PH12014500995A1 (en) 2014-08-04
EP2773643A4 (en) 2015-07-29
AU2012327183A8 (en) 2013-07-18
BR112014010631A2 (pt) 2017-04-25
AU2012327187A8 (en) 2013-07-25
CO7030960A2 (es) 2014-08-21
TW201326169A (zh) 2013-07-01
KR20140105451A (ko) 2014-09-01
IL232215A0 (en) 2014-06-30
WO2013067434A1 (en) 2013-05-10
JP2014532724A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
CR20140251A (es) Inhibidores de pak para el tratamiento del síndrome del x frágil
HUS2500019I1 (hu) A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
CO6791595A2 (es) Dispositivos para manipular artículos
PT2934145T (pt) Inibidores de histona demetilase
EP2734529A4 (en) BTK INHIBITORS
BR112013024052A2 (pt) artigo absorvente
EP2710007A4 (en) Kinase inhibitors
CO6970602A2 (es) Inhibidores de quinasa
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
PT2672973T (pt) Regime de administração para nitrocatecóis
PT2874630T (pt) Regime de dosagem para inibidores de janus quinase (jak)
BR112014000003A2 (pt) artigo absorvente
PL2772304T3 (pl) Urządzenia do oczyszczania poddanych nitrowaniu produktów
ES1075626Y (es) Protector para botellas
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
IL231126A0 (en) Use of an organic compound to treat Noonan syndrome
DK2723336T3 (da) Sammensætninger til behandling af fragilt X-syndrom
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
PT2872145T (pt) Benzazepinas fundidas para o tratamento da síndrome de tourette
ES1077556Y (es) Miniplantilla para sujecion del calzado